Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live on Sept. 16 at 8:30 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at one of the most prestigious healthcare investment conferences underscores Helus Pharma’s growing visibility in the mental health treatment sector. Morgan Stanley’s Global Healthcare Conference attracts top institutional investors, industry executives, and analysts, providing a platform for companies to showcase their pipelines and strategic visions. For Helus Pharma, this appearance offers an opportunity to engage directly with the investment community and to highlight its unique approach to addressing the large unmet need in depression, anxiety, and other mental health conditions.
Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists. These synthetic molecules are designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health.
The significance of this announcement extends beyond a simple conference appearance. It signals that Helus Pharma is entering a critical phase of clinical development and is actively positioning itself for potential commercialization. The Breakthrough Therapy Designation for HLP003 is particularly noteworthy, as it is reserved for drugs that may offer substantial improvement over existing therapies for serious conditions. This designation can expedite the development and review process, potentially bringing a new treatment option to patients sooner. For investors, the conference presentation may provide updates on trial progress, regulatory milestones, and market potential, which could influence the company’s valuation.
Moreover, the mental health treatment space has seen increased interest from both investors and the public, especially in the wake of the COVID-19 pandemic, which exacerbated rates of depression and anxiety worldwide. Helus Pharma’s focus on novel serotonergic agonists represents a differentiated approach that could address limitations of current antidepressants, such as delayed onset of action and treatment-resistant depression. If successful, the company’s NSAs could capture a significant share of a multi-billion-dollar market.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more, visit www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP. BioMedWire, a specialized communications platform, disseminated this announcement. As a clinical-stage company with multiple catalysts on the horizon, Helus Pharma’s participation in the Morgan Stanley conference could be a precursor to increased investor attention and strategic partnerships. The webcast and replay will allow a broad audience to access the discussion, further amplifying the company’s message.
